CN109311887B - 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途 - Google Patents
吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途 Download PDFInfo
- Publication number
- CN109311887B CN109311887B CN201780034861.3A CN201780034861A CN109311887B CN 109311887 B CN109311887 B CN 109311887B CN 201780034861 A CN201780034861 A CN 201780034861A CN 109311887 B CN109311887 B CN 109311887B
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- certain embodiments
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318929P | 2016-04-06 | 2016-04-06 | |
| US62/318,929 | 2016-04-06 | ||
| PCT/US2017/026280 WO2017176960A1 (en) | 2016-04-06 | 2017-04-06 | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109311887A CN109311887A (zh) | 2019-02-05 |
| CN109311887B true CN109311887B (zh) | 2022-09-13 |
Family
ID=60001526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780034861.3A Expired - Fee Related CN109311887B (zh) | 2016-04-06 | 2017-04-06 | 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11192892B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3440080A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7038063B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20180133461A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109311887B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017246455B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018070586A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3020287A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL262177B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018012211A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201808830YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017176960A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| EP3215511B1 (en) | 2014-11-06 | 2024-04-17 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| WO2016073889A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| MX388912B (es) | 2016-04-06 | 2025-03-20 | Lysosomal Therapeutics Inc | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos |
| WO2017176961A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR20180133461A (ko) | 2016-04-06 | 2018-12-14 | 리소소말 테라퓨틱스 인크. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도 |
| WO2017192930A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| CN110698484B (zh) * | 2019-06-05 | 2021-11-05 | 陕西理工大学 | 含吡唑并[1,5-a]嘧啶的衍生物、药用组合物及应用 |
| CN115108972A (zh) * | 2022-08-29 | 2022-09-27 | 北京迪泰医药科技有限公司 | 一种2-甲基-3-氟-5-溴吡啶的合成方法 |
| WO2025014639A2 (en) * | 2023-07-07 | 2025-01-16 | The Johns Hopkins University | Neutral sphingomyelinase inhibitors |
| WO2025146216A1 (zh) * | 2024-01-05 | 2025-07-10 | 成都赜灵生物医药科技有限公司 | 六并五氮杂环酰胺类化合物及其用途 |
| CN118184599A (zh) * | 2024-02-29 | 2024-06-14 | 重庆药友制药有限责任公司 | 一种阿莫奈韦中间体的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103534255A (zh) * | 2010-12-08 | 2014-01-22 | 美国健康及人类服务部 | 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| JP3763997B2 (ja) | 1999-05-13 | 2006-04-05 | 富士写真フイルム株式会社 | 感熱記録材料 |
| JP4331823B2 (ja) | 1999-05-21 | 2009-09-16 | 富士フイルム株式会社 | ピロロ[1,2−a]−1,3,5−トリアジン−4−オン系化合物 |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| JP4070966B2 (ja) | 2001-06-28 | 2008-04-02 | 株式会社カネボウ化粧品 | 新規ガラクトシルセラミド類縁体及び用途 |
| EP1440071B1 (en) | 2001-10-22 | 2005-10-26 | Pfizer Inc. | Imidazopyridine compounds as 5-ht 4? receptor modulators |
| CA2476757A1 (en) | 2002-03-01 | 2003-09-12 | Yamanouchi Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compound |
| DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
| WO2004026868A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Japan Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ[1,5−a]ピリミジン誘導体 |
| BRPI0409592A (pt) | 2003-04-21 | 2006-05-02 | Pfizer | compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3 |
| US20050137223A1 (en) | 2003-11-12 | 2005-06-23 | Amicus Therapeutics, Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| WO2005077953A1 (ja) | 2004-02-18 | 2005-08-25 | Banyu Pharmaceutical Co., Ltd. | 含窒素縮合へテロ芳香環誘導体 |
| EP1753422B1 (en) | 2004-05-14 | 2008-05-28 | The Cleveland Clinic Foundation | Small molecule inhibitors for mrp1 and other multidrug transporters |
| ATE383361T1 (de) * | 2004-06-21 | 2008-01-15 | Hoffmann La Roche | Pyrrazolopyrimidinderivate |
| DE502005003491D1 (de) | 2004-08-02 | 2008-05-08 | Sanol Arznei Schwarz Gmbh | Carboxamide des indolizins und seiner aza- und diazaderivate |
| DE102004049363A1 (de) | 2004-10-08 | 2006-04-13 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| AU2006206573B9 (en) | 2005-01-19 | 2011-09-29 | Merck Sharp & Dohme Corp. | Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| ATE512966T1 (de) | 2005-02-11 | 2011-07-15 | Hoffmann La Roche | Pyrazolo-pyrimidin-derivate als mglur2- antagonisten |
| DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| WO2006115168A1 (ja) | 2005-04-21 | 2006-11-02 | Dainippon Sumitomo Pharma Co., Ltd. | N-置換フェニルアセトアミド誘導体およびそれを含有する医薬組成物 |
| EP1878727A4 (en) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | 2-AMINOQUINAZOLINE DERIVATIVES |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EP1931675B1 (en) | 2005-10-06 | 2015-01-14 | Merck Sharp & Dohme Corp. | Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors |
| CN101296699B (zh) * | 2005-10-21 | 2013-01-02 | 田边三菱制药株式会社 | 吡唑并[1,5-a]嘧啶化合物 |
| CA2626789A1 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| US7795273B2 (en) | 2005-12-08 | 2010-09-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| DK2040548T3 (da) | 2006-06-23 | 2012-08-13 | Amicus Therapeutics Inc | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| WO2008019363A2 (en) | 2006-08-07 | 2008-02-14 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides as 5ht3 modulators |
| CA2670044A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| US20080255153A1 (en) | 2007-03-28 | 2008-10-16 | Biovitrum Ab (Publ) | New compounds |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| US20110053932A1 (en) | 2007-06-21 | 2011-03-03 | Irm Llc | Protein Kinase Inhibitors and Methods for Using Thereof |
| JP5479105B2 (ja) | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| CA2706946A1 (en) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| CA2718727A1 (en) | 2008-03-25 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AU2009243006B2 (en) | 2008-05-01 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Quinolines and related analogs as sirtuin modulators |
| TW201020258A (en) | 2008-10-14 | 2010-06-01 | Astrazeneca Ab | Chemical compounds 542 |
| BRPI0914404A2 (pt) | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| EP2688872A4 (en) | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| ES2561105T3 (es) | 2011-08-18 | 2016-02-24 | Nippon Shinyaku Co., Ltd. | Derivado heterocíclico como inhibidor de prostaglandina E sintasa microsómica (mPGES) |
| BR112014005110A2 (pt) | 2011-09-02 | 2017-04-18 | Bayer Ip Gmbh | pirimidinas aneladas substituídas e utilização das mesmas |
| US8961959B2 (en) | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| KR20140077963A (ko) * | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| RU2014140739A (ru) | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения |
| HK1199814A1 (en) | 2012-03-09 | 2015-07-24 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| CA2868484A1 (en) | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
| JP6231085B2 (ja) | 2012-05-31 | 2017-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アミノキナゾリン誘導体及びピリドピリミジン誘導体 |
| EP2865671B1 (en) | 2012-06-22 | 2017-11-01 | Sumitomo Chemical Company, Ltd | Fused heterocyclic compound |
| WO2014025651A1 (en) | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
| WO2014037340A1 (de) | 2012-09-05 | 2014-03-13 | Bayer Cropscience Ag | Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| EP2920181B1 (en) | 2012-11-16 | 2019-01-09 | University Health Network | Pyrazolopyrimidine compounds |
| EP2925750A1 (en) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| KR20140086002A (ko) | 2012-12-28 | 2014-07-08 | 한미약품 주식회사 | Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체 |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| JPWO2015012328A1 (ja) | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3035921A1 (en) | 2013-08-20 | 2016-06-29 | Bristol-Myers Squibb Company | Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| AR097543A1 (es) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| WO2015073267A1 (en) * | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| ES2895490T3 (es) | 2014-03-27 | 2022-02-21 | Acad Medisch Ct | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| WO2016073889A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| EP3215511B1 (en) | 2014-11-06 | 2024-04-17 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| WO2017004408A1 (en) | 2015-07-01 | 2017-01-05 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| US20190092789A1 (en) | 2015-09-04 | 2019-03-28 | Lysosomal Therapeutics Inc. | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| KR102782807B1 (ko) | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| WO2017140825A1 (en) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
| MX388912B (es) | 2016-04-06 | 2025-03-20 | Lysosomal Therapeutics Inc | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos |
| WO2017176961A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR20180133461A (ko) | 2016-04-06 | 2018-12-14 | 리소소말 테라퓨틱스 인크. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도 |
| EP3452045A1 (en) | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192929A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017192930A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| JP2021506920A (ja) | 2017-12-21 | 2021-02-22 | リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. | 結晶性の置換シクロヘキシルピラゾロ[1,5−a]ピリミジニルカルボキサミド化合物およびその治療的使用 |
-
2017
- 2017-04-06 KR KR1020187032153A patent/KR20180133461A/ko not_active Ceased
- 2017-04-06 KR KR1020237021557A patent/KR20230104752A9/ko not_active Withdrawn
- 2017-04-06 US US16/091,311 patent/US11192892B2/en active Active
- 2017-04-06 CN CN201780034861.3A patent/CN109311887B/zh not_active Expired - Fee Related
- 2017-04-06 AU AU2017246455A patent/AU2017246455B2/en not_active Ceased
- 2017-04-06 MX MX2018012211A patent/MX2018012211A/es unknown
- 2017-04-06 JP JP2018552683A patent/JP7038063B2/ja not_active Expired - Fee Related
- 2017-04-06 BR BR112018070586A patent/BR112018070586A8/pt not_active Application Discontinuation
- 2017-04-06 CA CA3020287A patent/CA3020287A1/en active Pending
- 2017-04-06 WO PCT/US2017/026280 patent/WO2017176960A1/en not_active Ceased
- 2017-04-06 EP EP17779797.4A patent/EP3440080A4/en not_active Withdrawn
- 2017-04-06 SG SG11201808830YA patent/SG11201808830YA/en unknown
- 2017-08-16 US US15/678,474 patent/US9840510B1/en active Active
-
2018
- 2018-10-07 IL IL262177A patent/IL262177B/en unknown
-
2019
- 2019-03-18 US US16/356,564 patent/US10934298B2/en active Active
-
2021
- 2021-10-25 US US17/509,353 patent/US12116369B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103534255A (zh) * | 2010-12-08 | 2014-01-22 | 美国健康及人类服务部 | 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018070586A2 (pt) | 2019-02-05 |
| KR20230104752A9 (ko) | 2024-11-15 |
| SG11201808830YA (en) | 2018-11-29 |
| US12116369B2 (en) | 2024-10-15 |
| US9840510B1 (en) | 2017-12-12 |
| BR112018070586A8 (pt) | 2023-03-14 |
| CA3020287A1 (en) | 2017-10-12 |
| JP2019510790A (ja) | 2019-04-18 |
| AU2017246455B2 (en) | 2021-09-30 |
| CN109311887A (zh) | 2019-02-05 |
| US20230098494A1 (en) | 2023-03-30 |
| JP7038063B2 (ja) | 2022-03-17 |
| EP3440080A1 (en) | 2019-02-13 |
| RU2018138688A (ru) | 2020-05-19 |
| IL262177A (en) | 2018-11-29 |
| US20190330213A1 (en) | 2019-10-31 |
| EP3440080A4 (en) | 2020-01-22 |
| US20200017507A1 (en) | 2020-01-16 |
| MX2018012211A (es) | 2019-03-28 |
| US10934298B2 (en) | 2021-03-02 |
| IL262177B (en) | 2022-06-01 |
| KR20180133461A (ko) | 2018-12-14 |
| KR20230104752A (ko) | 2023-07-10 |
| AU2017246455A1 (en) | 2018-10-25 |
| RU2018138688A3 (cg-RX-API-DMAC7.html) | 2020-08-31 |
| US20170349598A1 (en) | 2017-12-07 |
| WO2017176960A1 (en) | 2017-10-12 |
| US11192892B2 (en) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12116369B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | |
| CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
| CN109311902B (zh) | 取代的咪唑并[1,2-b]哒嗪、咪唑并[1,5-b]哒嗪、相关化合物及其用途 | |
| RU2655914C9 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| TWI845638B (zh) | Eed及prc2調節劑之巨環唑并吡啶衍生物 | |
| CN112771027A (zh) | 溶血磷脂酸受体拮抗剂及其制备方法 | |
| JP2019510790A5 (cg-RX-API-DMAC7.html) | ||
| CN110072857A (zh) | 作为造血前列腺素d合酶抑制剂的1,3-二取代的环丁酮或氮杂环丁烷衍生物 | |
| EP4051680B1 (en) | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase | |
| CN113302183A (zh) | 环脲 | |
| TW202039474A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法 | |
| CN113767101A (zh) | 具有抗乙型肝炎病毒(hbv)活性的新的吲哚-2-甲酰胺类化合物 | |
| CN114555604A (zh) | 药物化合物 | |
| EP3440083A1 (en) | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
| CN110809574A (zh) | 杂芳基二氢嘧啶衍生物和治疗乙型肝炎感染的方法 | |
| CN109111451A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103874697A (zh) | 二苯并氧杂*衍生物 | |
| JP6050238B2 (ja) | 新規なスピロインドリン化合物、及びそれを含有する医薬 | |
| CN117355506A (zh) | 包括氮杂环丁烷环脲的rip1调节剂、其制备和用途 | |
| RU2799332C2 (ru) | Пиразоло[1,5-a]пиримидинилкарбоксамиды и их применение для лечения патологических состояний | |
| HK40117760A (en) | Rip1 modulators, preparations, and uses thereof | |
| CN117980292A (zh) | 用于治疗正粘病毒感染的取代的吡啶酮化合物 | |
| HK40048952A (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof | |
| HK40041774A (en) | Lysophosphatidic acid receptor antagonists and preparation method therefor | |
| CN101370812A (zh) | 稠合的杂环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220111 Address after: Portuguese Saint May Didu Corona Du Applicant after: Bial R & D Investment Co.,Ltd. Address before: Massachusetts Applicant before: Bial biotechnology investment Co. Effective date of registration: 20220111 Address after: Massachusetts Applicant after: Bial biotechnology investment Co. Address before: Massachusetts Applicant before: LYSOSOMAL THERAPEUTICS Inc. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220913 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |